View Older Stories View More Recent Stories
-
Pfizer (PFE) Reports TALZENNA in Combination with XTANDI Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
-
Pfizer (PFE) Declares $0.42 Quarterly Dividend; 5.6% Yield
-
Popular stocks with increasing volume: PFE CCL BABA AAL MSTR NIO HOOD SOFI PDD
-
Pfizer (PFE) PT Raised to $31 at CFRA
-
Active options: PFE MSTR PLTR NIO MSFT OXY DJT RIOT BA
-
TD Cowen Reiterates Hold Rating on Pfizer (PFE)
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE)
-
Pfizer (PFE) invalidates two GSK (GSK) RSV vaccine patents in U.K.
-
Leerink Partners Reiterates Market Perform Rating on Pfizer (PFE)
-
Pfizer (PFE) option IV into Starboard has $1B stake and seeks changes, WSJ reports
-
Stocks expected to have increasing option volume: PEP TSLA AMD GM BA PFE PDD JD BABA
-
Activist Starboard Value Takes $1B Stake In Pfizer (PFE) - WSJ
-
Pfizer (PFE) Boosts Haleon (HLN) Offering Size To 640m Shares From 540m - Bloomberg
-
Pfizer (PFE) Intends To Sell About 540M Haleon (HLN) Shares - Bloomberg
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE)
-
Pfizer (PFE) Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA From Worldwide Markets
-
Pfizer (PFE), BioNTech (BNTX) gain positive CHMP opinon on Omicron KP.2-adapted COVID-19 vaccine in EU
-
Midday movers: Intel, Pfizer rise; Apple falls
-
Pfizer (PFE) Presents Positive Data from Phase 2 Study of Ponsegromab
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE)
-
Pfizer (PFE) Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
-
Rocket Pharmaceuticals (RCKT) Appoints Mikael Dolsten to its Board
-
Erste Group Downgrades Pfizer (PFE) to Hold, 'faces the challenge of continuing to grow'
-
Pfizer (PFE) Launches PfizerForAll Digital Platform to Sell Directly to Patients
-
10 most actionable policies if Harris wins & stock implications: Jefferies
-
Pfizer (PFE) and BioNTech (BNTX Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
-
Oppenheimer Reiterates Perform Rating on BioNTech (BNTX)
-
BMO Capital Reiterates Outperform Rating on BioNTech (BNTX)
-
Pfizer (PFE) and BioNTech (BNTX) Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
-
Pfizer (PFE) PT Raised to $30 at Citi
-
Midday movers: Robinhood, KeyCorp stock rise; Hawaiian Electric falls
-
Pfizer (PFE) Reports Top-Line Results of ABRYSVO for RSV in Immunocompromised Adults
-
Pfizer (PFE) PT Raised to $34 at Goldman Sachs
-
Pfizer hikes full-year outlook as Q2 results top estimates; shares up
-
Pfizer (PFE) Tops Q2 EPS by 14c; raises guidance
-
Stocks expected to have increasing option volume: PFE PYPL IT SYY GLW SOFI JBLU FFIV SFM
-
Pfizer (PFE) call put ratio 1.7 calls to 1 put into quarter results
-
Pfizer (PFE) call put ratio 2.3 calls to 1 put into quarter results
-
Popular stocks with increasing volume: GME F PFE COIN PLTR SMCI MMM CMG CRWD AVGO
-
Pfizer (PFE) Announces EU Approval of DURVEQTIX
-
Pfizer (PFE) Reports Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
-
Eli Lilly shares rise as weight-loss drug receives China approval
-
Biden Continues to Receive Paxlovid - President's Physician
-
ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024
-
Pfizer (PFE) PT Raised to $30 at UBS
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE)
-
Truist Securities Reiterates Buy Rating on Pfizer (PFE)
-
Midday movers: Nvidia and Apple fall as investors flee megacap tech
-
Pfizer (PFE) call put ratio 1.9 calls to 1 put after announcing was advancing the development of its key anti-obesity drug
-
Berenberg lifts its global obesity market sales forecasts to $150B by 2035
